Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Andrew Nsawotebba"'
Autor:
Pius Lutaaya, Ocung Guido, Hasifah Nakato Ssentamu, George William Kasule, Mary Akumu, Jupiter Marina Kabahita, Bernard Bagaya, Kenneth Musisi, Denis Oola, Anitah Katuramu, Andrew Nsawotebba, Edgar Kigozi, Faith Nakazzi, Joel Kabugo Solomon, Isa Adam, Orena Beatrice, Joanita Namutebi, Brenda Ayebare, Abdunoor Nyombi, Charles Manyonge, Ademun Julius Patrick, Kangave Fredrick, Moses L Joloba
Publikováno v:
BMC Infectious Diseases, Vol 24, Iss 1, Pp 1-8 (2024)
Abstract Introduction When COVID-19 hit the world in 2019, an enhanced focus on diagnostic testing for SARS-CoV-2 was essential for a successful pandemic response. Testing laboratories stretched their capabilities for the new coronavirus by adopting
Externí odkaz:
https://doaj.org/article/98a6c9f609594abebe30167c845d6780
Autor:
Andrew Nsawotebba, Ivan Ibanda, Dennis Mujuni, Susan Nabadda, Diana Nadunga, Joel Kabugo, Isa Adam, Enock Wekiya, Abdunoor Nyombi, Richard Nsubuga, Patrick Ademun, Kenneth Musisi, Fredrick Kangave, Moses Joloba
Publikováno v:
BMC Infectious Diseases, Vol 23, Iss 1, Pp 1-10 (2023)
Abstract Background Smear microscopy has remained the initial diagnostic test for presumptive tuberculosis (TB) patients in health facilities without the World Health Organization (WHO) recommended rapid diagnostic tools. In the Uganda TB laboratory
Externí odkaz:
https://doaj.org/article/e5f422d618f849eda367bff02f52af4c
Autor:
Dennis Mujuni, Dianah Linda Kasemire, Ivan Ibanda, Joel Kabugo, Andrew Nsawotebba, Jody E. Phelan, Robert Kaos Majwala, Didas Tugumisirize, Abdunoor Nyombi, Beatrice Orena, Irene Turyahabwe, Henry Byabajungu, Diana Nadunga, Kenneth Musisi, Moses Lutakoome Joloba, Willy Ssengooba
Publikováno v:
BMC Infectious Diseases, Vol 22, Iss 1, Pp 1-10 (2022)
Abstract Background Second-line drug resistance (SLD) among tuberculosis (TB) patients is a serious emerging challenge towards global control of the disease. We characterized SLD-resistance conferring-mutations among TB patients with rifampicin and/o
Externí odkaz:
https://doaj.org/article/b4fe0f0a25e346c2b75f7b87a1e86af9
Autor:
Andrew Nsawotebba, Ivan Ibanda, Isaac Ssewanyana, Patrick Ogwok, Francis Ocen, Christopher Okiira, Atek Kagirita, Dennis Mujuni, Didas Tugumisirize, Joel Kabugo, Abdunoor Nyombi, Robert Kaos Majwala, Bernard Ssentalo Bagaya, Simeon Kalyesubula-Kibuuka, Willy Ssengooba, Susan Nabadda
Publikováno v:
PLoS ONE, Vol 16, Iss 5, p e0251150 (2021)
IntroductionDespite the limited evidence for its effectiveness, thermal screening at points of entry has increasingly become a standard protocol in numerous parts of the globe in response to the COVID-19 pandemic. We sought to determine the effective
Externí odkaz:
https://doaj.org/article/a972b8e1ce0840179dd41a2389af3ae9
Autor:
Joel Kabugo, Joanita Namutebi, Dennis Mujuni, Andrew Nsawotebba, George William Kasule, Kenneth Musisi, Edgar Kigozi, Abdunoor Nyombi, Pius Lutaaya, Fredrick Kangave, Moses L Joloba
Publikováno v:
PLoS ONE, Vol 16, Iss 5, p e0251691 (2021)
BackgroundFollowing the WHO's endorsement of GeneXpert MTB/RIF assay for tuberculosis diagnosis in 2010, Uganda's ministry of health introduced the assay in its laboratory network in 2012. However, assessing the quality of the result produced from th
Externí odkaz:
https://doaj.org/article/365bdb1af19243b899c79407cdc352ec
Autor:
Justine Okello, Walter Okello, Sulman Muhanguzi, Clet Kakuru, Esther Nambo, Michael Omodo, Rose Anna Ademun, Felix Lakor Opiyo, Terence Odoch, Clovice Kankya, Frank Mwiine, Andrew Nsawotebba
Background: Foot and Mouth disease is a notifiable trans-boundary disease, which is endemic in a large area of Sub-Saharan Africa, including Uganda. Recently, the disease has emerged from new areas, with high impact, hence threatening the food securi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::784ea31456cbd4b30a2fb691a1e245df
https://doi.org/10.21203/rs.3.rs-2013492/v1
https://doi.org/10.21203/rs.3.rs-2013492/v1
Autor:
Frank Mugabe, Edward Kayongo, Godfrey Ekuka, Ronald Ssenyonga, Rhona Mijumbi-Deve, Peter Awongo Chaiga, Ismael Kawooya, Hannock Tweya, Andrew Nsawotebba
Publikováno v:
African Health Sciences
Background Drop out of presumptive TB individuals before making a final diagnosis poses a danger to the individual and their community. We aimed to determine the proportion of these presumptive TB drop outs and their associated factors in Bugembe Hea
Autor:
Dennis Mujuni, Willy Ssengooba, Ivan Ibanda, Joel Solomon Kabugo, Dianah Linda Kasemire, Elizabeth Nampewo, Andrew Nsawotebba, Jody E Phelan, Didas Tugumisirize, Beatrice Orena, Henry Byabajungu, Nathan Ntenkaire, Diana Nadunga, Julius Tumwine, Kenneth Musisi, Moses Joloba, Seungmo Kim, Ikwap Kokas, William Olaho Mukani, Joseph Kungu, Mathias Afayoa
Publikováno v:
F1000Research. 12:62
Background Increased tuberculosis disease burden arises as a result of low treatment success rates stemming from the emergence of second-line drug resistance. We aimed at determining the usefulness of second-line drug (SLD) resistance markers as prox
Autor:
Dennis Mujuni, Dianah Linda Kasemire, Ivan Ibanda, Joel Kabugo, Andrew Nsawotebba, Jody E. Phelan, Robert Kaos Majwala, Didas Tugumisirize, Abdunoor Nyombi, Beatrice Orena, Irene Turyahabwe, Henry Byabajungu, Diana Nadunga, Kenneth Musisi, Moses Lutakoome Joloba, Willy Ssengooba
Publikováno v:
BMC infectious diseases. 22(1)
Background Second-line drug resistance (SLD) among tuberculosis (TB) patients is a serious emerging challenge towards global control of the disease. We characterized SLD-resistance conferring-mutations among TB patients with rifampicin and/or isoniaz
Autor:
Ivan Ibanda, Robert Kaos Majwala, Andrew Nsawotebba, Joel Kabugo, Abdunoor Nyombi, Christopher Okiira, Benoni Munduku, Bernard S. Bagaya, Willy Ssengooba, Susan Nabadda, Enock Wekiya, Isa Adam, Moses Lutakoome Joloba, Patrick Ogwok, Simon Kalyesubula-Kibuuka, Lillian Linda, Dennis Mujuni, Francis Ocen, Isaac Ssewanyana, Morgan Otita, Atek Kagirita, Edgar Kigozi, Didas Tugumisirize
Introduction: The novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) that causes COVID-19 disease is a global challenge. Several countries have adopted testing, isolation, and tracing strategy towards the control of the COVID-19 pande
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::df33bb6e3ce659381d770087811699c1
https://doi.org/10.21203/rs.3.rs-154102/v1
https://doi.org/10.21203/rs.3.rs-154102/v1